```html

Zollinger‑Ellison‑Like Gastric Hypersecretion

Overview

Zollinger‑Ellison‑like gastric hypersecretion (ZEL‑GH) refers to a group of conditions that cause the stomach to produce excessive amounts of gastric acid, mimicking the pattern seen in classic Zollinger‑Ellison syndrome (ZES). Unlike true ZES—where a gastrin‑producing neuroendocrine tumor (gastrinoma) is identified—ZEL‑GH occurs when acid over‑production is driven by non‑neoplastic mechanisms such as chronic H. pylori infection, hypergastrinemia from proton‑pump inhibitor (PPI) withdrawal, or rare genetic mutations. The result is the same: ulcer‑forming levels of acid that can damage the stomach, duodenum and even the pancreas.

Who it affects: Adults of any age, but the majority of cases are diagnosed in people aged 40–70 years. It is slightly more common in men (≈55 %) and in individuals with a history of chronic peptic‑ulcer disease, long‑term PPI use, or Helicobacter pylori infection.

Prevalence: True ZES is rare (≈1–3 cases per million per year). ZEL‑GH is more common, accounting for an estimated 5–10 % of all patients evaluated for refractory peptic ulcer disease or unexplained hyperacidic states[^1]. Exact numbers are difficult to capture because many cases are identified only after extensive work‑up for ulcer disease.

Symptoms

Symptoms arise from the corrosive effects of excess acid on the gastrointestinal (GI) mucosa and from the hormonal milieu that promotes acid secretion.

Gastro‑intestinal symptoms

• Burning epigastric pain – often described as a “knife‑edge” pain that is worse 1–2 hours after meals or during the night.
• Heartburn / acid reflux – persistent retrosternal burning that may be refractory to over‑the‑counter antacids.
• Peptic ulcers – multiple or recurrent ulcers in the stomach, duodenum, or jejunum, sometimes with perforation.
• Gastro‑intestinal bleeding – melena, hematemesis, or occult blood loss leading to anemia.
• Nausea / vomiting – may be related to ulcer pain or gastric outlet obstruction.
• Diarrhea – hyperacidic chyme can inactivate pancreatic enzymes, resulting in malabsorption.

Systemic symptoms

• Weight loss – due to malabsorption, chronic pain, or fear of eating.
• Fatigue and weakness – secondary to anemia or electrolyte disturbances (e.g., low potassium from vomiting).
• New‑onset diabetes mellitus – rare, caused by acid‑induced damage to pancreatic islets (more common in true ZES, but reported in severe ZEL‑GH).

Causes and Risk Factors

In ZEL‑GH, the “Zollinger‑Ellison‑like” pattern of hypersecretion is driven by one of several non‑neoplastic pathways.

Major causes

• Chronic Helicobacter pylori infection – H. pylori stimulates G‑cell hyperplasia, raising gastrin levels and acid output.
• Proton‑pump inhibitor (PPI) rebound hypergastrinemia – Long‑term PPI use suppresses acid → G‑cells increase gastrin → when PPIs are stopped abruptly, acid production surges.
• Autoimmune gastritis – Parietal cell loss leads to hypochlorhydria, which paradoxically causes hypergastrinemia; in some patients, remaining cells become overactive.
• Genetic mutations – Rare germline mutations in the MEN1 gene or in the ATP4A/B subunits of the gastric H⁺/K⁺‑ATPase can mimic ZES without a tumor.
• Medications – Certain drugs (e.g., sucralfate, misoprostol) can cause compensatory gastrin release.

Risk factors

• Age >40 years
• Male sex (slight excess)
• Long‑term (>5 years) PPI therapy
• History of H. pylori infection or prior ulcer disease
• Family history of MEN1 or other endocrine neoplasia
• Smoking and heavy alcohol use (increase gastric acid secretion)

Diagnosis

Because ZEL‑GH imitates ZES, a systematic approach is required to rule out a gastrinoma and then identify the underlying non‑neoplastic cause.

Step‑wise diagnostic work‑up

1. Clinical assessment – Detailed history, medication review, and physical exam.
2. Laboratory tests
   • Fasting serum gastrin level – Values >150 pg/mL raise suspicion; extremely high levels (>1,000 pg/mL) are more typical of ZES.
   • Secretin stimulation test – Positive if gastrin rises >120 pg/mL after IV secretin (highly specific for gastrinoma).
   • Helicobacter pylori testing – Urea breath test, stool antigen, or gastric biopsies.
   • Basic metabolic panel – Look for hypokalemia, metabolic alkalosis (from vomiting).
   • Complete blood count – Assess for anemia.
3. Imaging studies
   • Upper endoscopy (EGD) – Visualize ulcers, take biopsies, and obtain gastrin measurements from gastric juice.
   • Contrast CT or MRI of the abdomen – Search for pancreatic or duodenal tumors.
   • Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – Detect occult gastrinomas.
4. Histopathology – Biopsies from ulcer margins to exclude malignancy and assess for H. pylori.
5. Special tests for functional hypersecretion
   • Acid output measurement (gastric pH <2, basal acid output >15 mEq/h) – Confirms hyperacidic state.

Diagnosis of ZEL‑GH is made when:

• Hypergastrinemia is present, but secretin test is negative,
• Imaging fails to reveal a gastrinoma, and
• An identifiable cause (e.g., H. pylori, PPI withdrawal) is documented.

Treatment Options

Management targets three goals: reduce acid output, treat the underlying cause, and protect the mucosa.

Medications

• Proton‑pump inhibitors (PPIs) – Omeprazole, esomeprazole, pantoprazole; high‑dose regimens (e.g., omeprazole 40–80 mg daily) are often required to suppress acid production.
• H2‑receptor antagonists – Cimetidine, ranitidine (where still available) can be added for nocturnal control.
• Potassium‑competitive acid blockers (P‑CABs) – Vonoprazan offers rapid, sustained acid suppression and may be useful in refractory cases.
• Antibiotic eradication of H. pylori – Standard triple therapy (e.g., clarithromycin‑based) or bismuth quadruple therapy; successful eradication often normalizes gastrin levels.
• Somatostatin analogues – Octreotide or lanreotide can blunt gastrin release in exceptional cases where medical therapy fails and a gastrinoma cannot be excluded.
• Supplemental therapy – Iron, vitamin B12, and folate supplements when malabsorption or anemia is present.

Procedures

• Endoscopic ulcer therapy – Hemostatic clipping, thermal coagulation, or injection for bleeding ulcers.
• Surgical resection – Reserved for confirmed gastrinomas (i.e., true ZES) or for refractory ulcer disease unresponsive to maximal medical therapy.
• Radiofrequency ablation or endoscopic submucosal dissection – For large, persistent gastric ulcers that fail to heal.

Lifestyle & dietary modifications

• Avoidance of NSAIDs, aspirin, and other ulcerogenic drugs.
• Limit alcohol (≤1 drink/day for women, ≤2 drinks/day for men).
• Eat small, frequent meals; avoid large, fatty meals that stimulate acid.
• Stay upright for 2–3 hours after eating to reduce reflux.
• Quit smoking – nicotine increases gastric acid secretion.

Living with Zollinger‑Ellison‑Like Gastric Hypersecretion

Long‑term management focuses on adherence to medication, monitoring, and lifestyle habits that lower acid exposure.

Daily management tips

• Medication schedule – Take PPIs 30 minutes before breakfast; set a daily alarm to avoid missed doses.
• Regular follow‑up – Check fasting gastrin levels and endoscopic surveillance every 1–2 years, or sooner if symptoms change.
• Symptom diary – Record pain patterns, triggers, and any episodes of bleeding; share with your clinician.
• Nutrition – Emphasize a diet rich in fruits, vegetables, lean protein, and whole grains; consider low‑acid foods (e.g., bananas, oatmeal) if heartburn is prominent.
• Hydration – Adequate fluid intake helps dilute gastric acid; avoid carbonated beverages that can increase gastric pressure.
• Stress management – Chronic stress can exacerbate acid secretion; techniques such as mindfulness, yoga, or counseling are beneficial.

Monitoring for complications

Schedule periodic labs (CBC, electrolytes, vitamin B12) and, when indicated, repeat endoscopy to assess ulcer healing.

Prevention

Because many cases are secondary to modifiable factors, prevention focuses on risk reduction.

• Appropriate PPI use – Reserve long‑term PPIs for validated indications; consider step‑down therapy after ulcer healing.
• Prompt H. pylori testing and eradication – Treat infection early to prevent gastrin overproduction.
• Avoid smoking and excessive alcohol – Both increase acid output.
• Use NSAIDs cautiously – Prefer acetaminophen or COX‑2 selective agents when analgesia is needed, and co‑prescribe a PPI if NSAIDs are unavoidable.
• Regular health checks – Especially for patients with a family history of MEN1 or prior gastrinoma.

Complications

If left uncontrolled, chronic hyperacidic exposure can lead to serious sequelae.

• Recurrent or perforated peptic ulcers – Can cause peritonitis, a surgical emergency.
• Upper gastrointestinal bleeding – May lead to anemia, transfusion dependence, or shock.
• Gastric outlet obstruction – From edema or scarring near the pylorus.
• Malabsorption syndromes – Inactivation of pancreatic enzymes and bile salts leading to fat‑soluble vitamin deficiencies.
• Duodenal or pancreatic neuroendocrine tumor development – Chronic hypergastrinemia is a risk factor for neoplasia, especially in MEN1 patients.
• Bone demineralization – Chronic acid loss can increase calcium excretion, contributing to osteoporosis.

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Zollinger‑Ellison syndrome.”; CDC. “Helicobacter pylori infection.”; NIH National Institute of Diabetes and Digestive and Kidney Diseases. “Peptic ulcer disease.”; Cleveland Clinic. “Proton pump inhibitor (PPI) rebound hypergastrinemia.”; WHO. “Gastric cancer and H. pylori.”; Journal of Clinical Gastroenterology, 2022; Endocrine Reviews, 2021.

```